Browse hierarchy: [Gastroenterology, Urology (GU)](/submissions/GU) → [Subpart F — Therapeutic Devices](/submissions/GU/subpart-f%E2%80%94therapeutic-devices) → [21 CFR 876.5305](/submissions/GU/subpart-f%E2%80%94therapeutic-devices/876.5305) → QXM — Implanted Tibial Electrical Urinary Continence Device

# QXM · Implanted Tibial Electrical Urinary Continence Device

_Gastroenterology, Urology · 21 CFR 876.5305 · Class 2_

**Canonical URL:** https://fda.innolitics.com/submissions/GU/subpart-f%E2%80%94therapeutic-devices/QXM

## Overview

- **Product Code:** QXM
- **Device Name:** Implanted Tibial Electrical Urinary Continence Device
- **Regulation:** [21 CFR 876.5305](/submissions/GU/subpart-f%E2%80%94therapeutic-devices/876.5305)
- **Device Class:** 2
- **Review Panel:** [Gastroenterology, Urology](/submissions/GU)
- **Implant:** yes

## Identification

An implanted tibial electrical urinary continence device is an implanted prescription device that receives power from a non-implanted external power source to provide electrical stimulation of the tibial nerve in proximity to the ankle. The device is intended for the treatment of overactive bladder related symptoms of urge urinary incontinence, urinary urgency, urinary frequency and nocturia.

## Classification Rationale

Class II (special controls). The device is classified as Class II because the probable benefits outweigh the probable risks, and the risks can be mitigated by the use of general and the identified special controls.

## Special Controls

In combination with the general controls of the FD&C Act, an implanted tibial electrical urinary continence device is subject to the following special controls:

## Recent Cleared Devices (3 of 3)

| Record | Device Name | Applicant | Decision Date | Decision |
| --- | --- | --- | --- | --- |
| [K252391](https://fda.innolitics.com/submissions/GU/subpart-f%E2%80%94therapeutic-devices/QXM/K252391.md) | Revi System | Bluewind Medical , Ltd. | Dec 12, 2025 | SESE |
| [K240037](https://fda.innolitics.com/submissions/GU/subpart-f%E2%80%94therapeutic-devices/QXM/K240037.md) | Revi™ System | Bluewind Medical , Ltd. | May 2, 2024 | SESE |
| [DEN220073](https://fda.innolitics.com/submissions/GU/subpart-f%E2%80%94therapeutic-devices/QXM/DEN220073.md) | Revi System | Bluewind Medical , Ltd. | Aug 16, 2023 | DENG |

## Top Applicants

- Bluewind Medical , Ltd. — 3 clearances

---

**Source:** [https://fda.innolitics.com/submissions/GU/subpart-f%E2%80%94therapeutic-devices/QXM](https://fda.innolitics.com/submissions/GU/subpart-f%E2%80%94therapeutic-devices/QXM)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com